Extended spectrum beta-lactamases (ESBL) are bacterial enzymes that render certain antibiotics ineffective and make bacteria multidrug-resistant.
Beta-Laktamasen mit erweitertem Spektrum
ESBLs result from mutation of the common beta-lactamase. They confer resistance to several beta-lactam antibiotics. This makes ESBL-producing enterobacteriaceae multidrug-resistant, a situation particularly problematic in hospitals.
The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of ...